Patents by Inventor Ralph Mazitschek

Ralph Mazitschek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY
    Publication number: 20240139187
    Abstract: Formulations of HDAC6 inhibitors passing through the blood brain barrier in hypothalamus and inhibiting HDAC6 in the arctuate AgRP neurons in the hypothalamus, are effective to cause weight loss in obese individuals. These inhibitors also restore leptin sensitivity in leptin-resistant individuals.
    Type: Application
    Filed: May 26, 2023
    Publication date: May 2, 2024
    Inventors: Umut Ozcan, Ralph Mazitschek, Dongxian Guan
  • HDAC1,2 inhibitors
    Patent number: 11858919
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: January 2, 2024
    Assignee: Regenacy Pharmaceuticals, Inc.
    Inventors: John H. Van Duzer, Ralph Mazitschek, Charles Blum
  • PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS
    Publication number: 20230348389
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: May 5, 2023
    Publication date: November 2, 2023
    Inventors: John H. van Duzer, Ralph Mazitschek
  • TR-FRET BASED ASSAY FOR DETECTION OF ANTIBODIES IN SEROLOGICAL SAMPLES
    Publication number: 20230341394
    Abstract: The present invention relates to a homogeneous, time resolved, Förster resonance energy transfer (TR-FRET)-based method for detection of SARS-CoV-2, SARS CoV-1, and MERS-CoV antibodies in a patient fluid sample.
    Type: Application
    Filed: August 16, 2021
    Publication date: October 26, 2023
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Eric Fischer, Radoslaw Nowak, Hong Yue, Daan Overwijn, Ralph Mazitschek, Neil Connor Payne
  • Analogs of celastrol
    Patent number: 11753436
    Abstract: Described herein, inter alia, are compositions and methods for treating or preventing obesity and using the same.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: September 12, 2023
    Assignee: ERX Pharmaceuticals Corporation
    Inventors: Ralph Mazitschek, Yanbing Ding, Kaisheng Shen
  • Inhibitors of prolyl-tRNA-synthetase
    Patent number: 11708353
    Abstract: The present application provides compounds, such as compounds of Formula Ia, which are inhibitors of aminoacyl tRNA-synthetase (e.g., prolyl-tRNA-synthetase), and which are useful for treating disorders associated with aminoacyl tRNA-synthetase activity and/or expression. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also provided.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: July 25, 2023
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Ralph Mazitschek, Sofia A. Santos, Mark A. Tye, N. Connor Payne, Dyann F. Wirth
  • Piperidine derivatives as HDAC1/2 inhibitors
    Patent number: 11702389
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: July 18, 2023
    Assignee: REGENACY PHARMACEUTICALS, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
    Patent number: 11617750
    Abstract: The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: April 4, 2023
    Assignee: Acetylon Pharmaceuticals, Inc.
    Inventors: John H. van Duzer, Ralph Mazitschek, Walter Ogier, James E. Bradner, Guoxiang Huang, Dejian Xie, Nan Yu
  • Photoswitchable HDAC inhibitors
    Patent number: 11596691
    Abstract: This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: March 7, 2023
    Assignee: The General Hospital Corporation
    Inventors: Ralph Mazitschek, Balaram Ghosh, James Adam Hendricks, Surya Reis, Stephen John Haggarty
  • Substituted piperazines as selective HDAC1,2 inhibitors
    Patent number: 11542242
    Abstract: Provided herein are compounds of Formula IV, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: January 3, 2023
    Assignee: REGENACY PHARMACEUTICALS, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek
  • METHODS AND MATERIALS FOR MODULATING NRF2 PATHWAY
    Publication number: 20220395577
    Abstract: The present application provides methods and compounds of modulating Nrf2 pathway. Methods for treating cancer and neurodegenerative conditions are also provided.
    Type: Application
    Filed: October 2, 2020
    Publication date: December 15, 2022
    Inventors: Bakhos Tannous, Christian Badr, Ralph Mazitschek, Neil Connor Payne
  • SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS
    Publication number: 20220281833
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: May 17, 2022
    Publication date: September 8, 2022
    Inventors: John H. van Duzer, Ralph Mazitschek
  • HDAC1,2 Inhibitors
    Publication number: 20220033388
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: September 25, 2019
    Publication date: February 3, 2022
    Inventors: John H. VAN DUZER, Ralph MAZITSCHEK, Charles BLUM
  • Complexes and Ligands
    Publication number: 20220025254
    Abstract: The present application provides ligands and fluorescent or luminescent complexes comprising these ligands.
    Type: Application
    Filed: October 22, 2019
    Publication date: January 27, 2022
    Inventors: Ralph Mazitschek, N. Connor Payne, Alena Kalyakina
  • PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS
    Publication number: 20210332036
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: October 9, 2019
    Publication date: October 28, 2021
    Inventors: John H. VAN DUZER, Ralph MAZITSCHEK, Charles BLUM, Matthew B. JARPE
  • COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF
    Publication number: 20210275482
    Abstract: Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.
    Type: Application
    Filed: May 21, 2021
    Publication date: September 9, 2021
    Inventors: Umut Ozcan, Joseph Majzoub, Ralph Mazitschek
  • Inhibitors of Prolyl-tRNA-Synthetase
    Publication number: 20210253558
    Abstract: The present application provides compounds which are inhibitors of aminoacyl tRNA-synthetase (e.g., prolyl-tRNA-synthetase) and are useful for treating disorders associated with aminoacyl tRNA-synthetase activity and/or expression. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also provided.
    Type: Application
    Filed: June 10, 2019
    Publication date: August 19, 2021
    Inventors: Ralph Mazitschek, Sofia A. Santos, Mark A. Tye, N. Connor Payne, Dyann F. Wirth
  • Compounds for the treatment of obesity and methods of use thereof
    Patent number: 11045439
    Abstract: Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: June 29, 2021
    Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, THE GENERAL HOSPITAL CORPORATION
    Inventors: Umut Ozcan, Joseph Majzoub, Ralph Mazitschek
  • PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS
    Publication number: 20210179559
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: February 24, 2021
    Publication date: June 17, 2021
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Inhibitors of histone deacetylase
    Patent number: RE49240
    Abstract: The present invention relates to compounds which inhibit histone deacetylase activity and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing these compounds. The present invention also relates to methods of treating and preventing hematological cell proliferative disorders, such as multiple myeloma, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: October 11, 2022
    Assignee: The General Hospital Corporation
    Inventors: Ralph Mazitschek, Teru Hideshima, Kenneth C. Anderson, Stephen J. Haggarty, Balaram Ghosh